Main Article Content
Background: Ovarian cancer is a leading cause of death, primarily because of delays in diagnosis. Epithelial ovarian cancer (EOC) is the most common histological form of ovarian cancer. The results of treatment depend on the stage and the presence of a residual tumour after surgery.
Objective: The primary objective was to study the histopathological subtype of EOC in patients at Prapokklao Hospital. The secondary objectives included studying the outcomes and factors that affect the outcomes of surgery and treatment in EOC patients.
Materials and methods: This study is a hospital-based retrospective descriptive study which analysed the data of EOC patients in the Division of Obstetrics and Gynaecology at Prapokklao Hospital between January 2011 and December 2016. Incidences of EOC were counted, while the stage, results of surgery and adjuvant treatment after surgery were recorded.
Results: A total of 172 patients were included in the sampling. The most common form identified was serous cystadenocarcinoma (51 cases, 29.7%). The results of surgery were not statistically significant in terms of difference between histopathological subtypes (p = 0.145). Further, there was no difference in treatment method (p = 0.151), metastatic site of disease (p = 0.364) between less and more aggressive histopathological subtypes. Obesity (AOR = 2.37, 95%CI 1.09-5.15, p = 0.03) and advanced stage (AOR = 4.78, 95%CI 2.11-10.78, p < 0.001) were factors that related to suboptimal surgery in EOC patients.
Conclusions: In this study, serous cystadenocarcinoma was found to be the most common of histopathological subtypes. Histopathological subtypes do not affect the outcome of surgery. Suboptimal surgery was found to be more prevalent in patients with obesity and advanced stages of illness.
Keywords: epithelial ovarian cancer; outcome of surgery; treatment; risk factor
complete picture?. Ann Oncol 2005;16: 4-6.
2. Berek JS, Longacre TA, Friedlander M. Ovarian, Follopian tube and peritoneal cancer.
In: Berek JS, Berek DL, editor. Berek and Novak‘s gynecology. 15th ed. Philadelphia:
Williams and Wilkins; 2012, 1350-427.
3. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer.
Br J Cancer 2001; 85: 944-52.
4 .Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality
in Europe in 2008. Eur J Cancer 2010; 46: 765-81.
5. Ghosh A, Ghartimagar D, Thapa S, Sathian B, Narasimhan R, Talwar OP. Ovarian tumors:
pattern of histomorphological types- a 10 years study in tertiary referral center and review of
literature. Kathmandu Univ Med J 2016: 14(54):153-8.
6. Gram IT, Lukanova A, Brill I, Braaten T, Lund E, Lundin E, et al. Cigarette smoking and
risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer
7. Heidemann LN, Hartwell D, Heidemann CH, Jochumsem KM. The relation between
endometriosis and ovariancancer a review. Acta Obstet Gynecol Scand 2014; 93: 20–31.
8 .Hein A, Thiel FC, Bayer CM, Fasching PA, Haberle L, Lux MP,et al. Hormone replacement
therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 2013; 22:52–8.
9 . Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungrung, Sangrajrang S,
et al. Cancer in Thailand Vol.. VIII, 2010-2012 [Internet], Bangkok: New Thammada Press;
2015. [cited 2018 Jan 23]. Available from: https://www.nci.go.th/th/File_download/
10. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of
ovarian cancer? a systematic review. Gyneco lOncol 2006;103:1122-9.
11 . Khuhaprema T, Attasara P, Sriplung H, Wiangnon S, Sangrajrang. .Cancer in Thailand Vol. VII
2007-2009. Bangkok: Ministry of public health; 2013. [cited 2018 Jan 23]. Available from:
12 .Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM, Edwards CL.
Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol
1990; 39: 337-46.
13. Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual
disease, FIGO Substage, tumor histology, and grade in patients with FIGO stage III ovarian
cancer. Gynecol Oncol 1995;56:175-80.
14. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al.
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with
stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
15. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The
new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its
clinical implications . Arc Gynecol Obstet 2016; 293:695-700.
16. Murthy N S, Shalini S, Suman G, et al (2009). Changing trends in incidence of ovarian cancer-
the Indian scenario. Asian Pac J Cancer Prev 2009;10:1025-30.
17. Onyiaorah IV, Anunobi CC, Banjo AA, Fatima AA, Nwankwo KC. Histopathological patterns of
ovarian tumors seen in Lagos University Teching Hospital: a ten year retrospective study.
Niq Q J Hosp Med 2011; 21:114-8
18. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III
trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with
optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin
Oncol 2003;,21: 3194-200.
19 .Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and
ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285:1460-5.
20. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
21. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, et al. .Endometrioid
epithelial ovarian cancer: 20 years of prospectively collected data from a single center.
Cancer 2008; 112:2211-20.
22. Sung PL, Chang YH, Chao KC, Chuang CM. Global distribution pattern of histological
subtypes of epithelial ovarian cancer: a database analysis and systematic review.
23. Tidy J, Mason WP. Endometrioid carcinoma of the ovary: a retrospective study. Br J
ObstetGynaecol 1988; 95:1165-9.
24. Kunpalin Y, Triratanachat S, Tantbirojn P. Proportion of ovarian cancers in overall ovarian
masses in Thailand. Asian Pac J Cancer Prev 2014; 15:7929-34.
25. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube,
and primary peritoneal cancer. Arch GynecolObstet 2014; 290: 839-42.